Tumor mutational load predicts survival after immunotherapy across multiple cancer typesRobert Samstein, Ronald P. DeMatteo, Chung‐Han Lee et al.|Nature Genetics|2019Cited by 4.4k
Soft Tissue Sarcoma, Version 2.2018, NCCN Clinical Practice Guidelines in OncologyMargaret von Mehren, Jillian L. Scavone, R. Lor Randall et al.|Journal of the National Comprehensive Cancer Network|2018Cited by 733
Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trialWilliam D. Tap, Andrew J. Wagner, Qiang Wang et al.|The Lancet|2019Cited by 472
Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue SarcomaMrinal M. Gounder, Albiruni Ryan Abdul Razak, Alona Zer et al.|Journal of Clinical Oncology|2016Cited by 165
Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma NetworkGeorge D. Demetri, Jean‐Yves Blay, Cristina R. Antonescu et al.|Annals of Oncology|2020Cited by 145